A Rapidly Moving Market: NGS Testing in Cancer in the US and EU, Upcoming Webinar Hosted by Xtalks

Share Article

While next-generation sequencuing (NGS) becomes a common feature of clinical practice, global regulators and insurers have yet to come up with a unified reimbursement policy. Join industry experts in this free webinar to learn about the clinical and commercial reality of NGS cancer testing and their predictions for what lies ahead in the US and EU.

Xtalks Life Science Webinars

In the United States, both large commercial labs and large health systems offer NGS tumor testing, and it is anticipated that this landscape will change the availability of a US Food and Drug Administration (FDA)-approved NGS tumor panel.

Even though next-generation sequencing (NGS) cancer testing has moved from a rarity to a common feature of clinical practice in recent years, reimbursement policies for NGS testing still vary widely among private and public insurers across different countries.

In the United States, both large commercial labs and large health systems offer NGS tumor testing, and it is anticipated that this landscape will change the availability of a US Food and Drug Administration (FDA)-approved NGS tumor panel. Meanwhile, healthcare systems in Europe are taking what is, in many ways, a very different approach to reimbursement of clinical sequencing with NGS. In France, for example, a network of regional laboratories will be reimbursed to provide molecular testing services. Similarly, genomic laboratory hubs will provide access to whole genome sequencing in the UK beginning in 2019.

Join Dr. Bruce Quinn, MD, PhD, Principal at Bruce Quinn Associates LLC and Joseph V. Ferrara, President & CEO of Boston Healthcare Associates in a live webinar on Tuesday, May 21, 2019 at 11am EDT (4pm BST/UK) to learn about:

  • An overview of NGS testing in cancer
  • Recent policy changes and announcements for NGS coverage, reimbursement and determination
  • Predictions for what lies ahead for the industry in the US and EU

For more information or to register for this event, visit A Rapidly Moving Market: NGS Testing in Cancer in the US and EU.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Candice Tang
Visit website

Media

Visit: www.bostonhealthcare.com